Skip to main content

TROPION-PanTumor01 Trial With Datopotamab Deruxtecan (Dato-Dxd or DS-1062a)

*September 2021*

Dato-DXd is an ADC targeting TROP2 and delivering a potent topoisomerase I inhibitor. Efficacy seen in prior reports but this presentation focused on the subset of patients with NSCLC harboring an actionable driver alteration. (Dr. Stephen V. Liu)


TROPION-PanTumor01 Trial
Safety/Toxicity: Grade 3+ treatment emergent adverse events (TEAEs) seen in 38% of patients. 27% dose interruption and 15% dose reduction for TEAEs. Most common were nausea, stomatitis, fatigue, alopecia – mostly G1-2 and consistent with topo inhibitor toxicity. Only 1 incident of interstitial lung disease – but it was fatal.

In driver+ NSCLC, Dato-DXd had a Response Rate (RR)  of 35% with a median Duration of Response (DOR) of 9.5m. Activity seen post- TKI for EGFR and ALK. Small sample here but encouraging to see activity — yet another option worth investigation. A versatile agent that can fill an unmet need, though not clearly related to the fact that a driver is present. So maybe not more likely to respond but not less likely either. (Dr. Stephen V. Liu)  Read more.